Systemic Mastocytosis – Pipeline Review, H2 2012

Publisher Name :
Date:31-Oct-2012
No. of pages: 37
Inquire Before Buying

Systemic Mastocytosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘Systemic Mastocytosis – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Systemic Mastocytosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Mastocytosis. Systemic Mastocytosis – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Systemic Mastocytosis.
- A review of the Systemic Mastocytosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Systemic Mastocytosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Systemic Mastocytosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Systemic Mastocytosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Systemic Mastocytosis – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Systemic Mastocytosis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Systemic Mastocytosis 7
Systemic Mastocytosis Therapeutics under Development by Companies 9
Systemic Mastocytosis Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Systemic Mastocytosis Therapeutics - Products under Development by Companies 14
Systemic Mastocytosis Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Systemic Mastocytosis Therapeutics Development 16
Novartis AG 16
Pharmacyclics, Inc. 17
AB Science 18
Systemic Mastocytosis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
midostaurin - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
PCI-45261 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
masitinib - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PKC-412 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
thalidomide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Systemic Mastocytosis Therapeutics - Drug Profile Updates 31
Systemic Mastocytosis Therapeutics - Discontinued Products 34
Systemic Mastocytosis Therapeutics - Dormant Products 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables
Number of Products Under Development for Systemic Mastocytosis, H2 2012 7
Products under Development for Systemic Mastocytosis - Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Novartis AG, H2 2012 16
Pharmacyclics, Inc., H2 2012 17
AB Science, H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Systemic Mastocytosis Therapeutics - Drug Profile Updates 31
Systemic Mastocytosis Therapeutics - Discontinued Products 34
Systemic Mastocytosis Therapeutics - Dormant Products 35

List of Figures
Number of Products under Development for Systemic Mastocytosis, H2 2012 7
Products under Development for Systemic Mastocytosis - Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • OpportunityAnalyzer: Graft-Versus-Host Disease – Opportunity Analysis and Forecasts to 2018
    Published: 21-Aug-2014        Price: US $5995 Onwards        Pages: 253
    The main drivers of growth in graft versus host disease over the 2013-2018 forecast period include the increasing numbers of allogeneic hematopoietic stem cell transplants and the increasing use of biologic off-label and marketed therapies in the 6MM.Sanofi is a key player in the GVHD market with Thymoglobuline and Lemtrada by infiltrating prophylaxis, aGVHD and cGVHD. J&J’s Remicade, has gained a significant patent share of the aGVHD patient group, as it is one of the few drugs that a......
  • Australia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 135
    BMI View: Over 300 drug formulations listed on the Pharmaceutical Benefits Scheme (PBS) will be subject to price reduction from October 1 2014, following the first simplified price disclosure (SPD) cycle in Australia. As a result, the prices of the affected drugs will be lowered by 20% on average, from those in April 2014. The Australian government continues to push price controls on pharmaceuticals. This is a reflection of the fact that high prices are no longer accepted by patients and nationa......
  • Global Heart Valve Repair and Replacement Market 2014-2018
    Published: 20-Aug-2014        Price: US $2500 Onwards        Pages: 78
    Heart valves are structures in the human heart which control the flow of blood during the cardiac cycle. A person affected with heart valve diseases such as valvular stenosis, valvular insufficiency or regurgitation, prolapse, and atresia requires the repair or replacement of the natural heart valves. Aortic valves cannot be repaired; therefore, it is replaced using prosthetic heart valves. However, the mitral, tricuspid, and pulmonary valves can be repaired as well as replaced depending on the ......
  • Croatia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 102
    BMI View: Heavy price cuts and margin restrictions within the pharmaceutical supply chain threaten to cause drug shortages and weaken the supply chain within Croatia, with product withdrawals expected and the HZZO braced for revolt from pharmacies and wholesalers. We forecast weak pharmaceutical market growth over the next decade, in light of Croatia's acceding to EU pressure to rein in its budget deficit. Liquidity issues and payment terms will remain unfavourable in 2014, but with Croatia's ec......
  • Global Meningococcal Vaccines Market 2014-2018
    Published: 20-Aug-2014        Price: US $2500 Onwards        Pages: 78
    Meningitis is characterized by the inflammation of the protective lining (meninges) present around the brain and the spinal cord. On the basis of its underlying cause, meningitis can be classified into infectious and non-infectious meningitis. In terms of the type of organism, infectious meningitis can be sub-divided into bacterial meningitis, viral meningitis, fungal meningitis, and parasitic meningitis. Bacterial meningitis is the life-threatening form of infectious meningitis, which can occur......
  • Kenya Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 106
    BMI View: Investment into Kenya's healthcare sector by pharmaceutical and medical device companies is an advisable business strategy - as highlighted by the high growth forecast in healthcare spending between 2013 and 2018. However, we note that there are downside risks to our forecast, including government inefficiencies and the out-of-pocket characteristics of the market, which will act as challenges for companies looking for a rapid return on investment. Headline Expenditure Projections ? Pha......
  • Global Multiple Sclerosis Drugs Market 2014-2018
    Published: 20-Aug-2014        Price: US $3000 Onwards        Pages: 102
    Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, and neurodegeneration. The myelin sheath is damaged because of an abnormal response by the immune system, which targets neurons within the central nervous system (CNS). It is a potentially debilitating disease in which the damage of the myelin sheath causes disruption in the communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subje......
  • Latvia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 107
    BMI View: Latvia's macroeconomic environment continues to improve at the same time as smooth transitions to a new currency and new Prime Minister. Market growth forecasts are strong although the country will continue to present a modest opportunity to larger multinational companies on account of its relatively small market size. Meanwhile, tensions between Ukraine and Russia may provide challenges for local manufacturers looking towards exports to Russia to boost revenue. Headline Expenditure Pr......
  • Global Orthopedic Soft Tissue Repair Devices Market 2014-2018
    Published: 20-Aug-2014        Price: US $2500 Onwards        Pages: 71
    Orthopedic soft tissues are the mass of cells that connect, support, or surround bones. There are several types of orthopedic soft tissues such as tendons, ligaments, cartilage, fascia, and other fibrous tissues. Repetitive use, accidents, injuries, and the degeneration of these tissues with age result in wear and tear in these tissues. Orthopedic soft tissue repair devices are used to repair any damage to these tissues either through open surgical procedures or MI procedures such as arthroscopy......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs